Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Cannabis improves symptoms of Crohn’s disease despite having no effect on gut inflammation

In the first study of its kind, cannabis oil has been shown to significantly improve the symptoms of Crohn’s disease and the quality of life of sufferers but, contrary to previous medical thinking, has no effect on gut inflammation. In a randomised, placebo-controlled study, researchers from Israel have shown that cannabis can produce clinical remission…
Read More →

Medical marijuana users tell their stories to Medical Cannabis Study Commission

Thursday, the Medical Cannabis Study Commission held its third meeting. The Commission has been tasked with presenting a policy recommendation to the legislature on exactly what the best medical marijuana bill should look like. The Commission held a public hearing in which a number of medical marijuana users claimed that the drug has benefitted them.…
Read More →

Medical Marijuana a Hit With Seniors

In a new survey, those who turned to it for treating chronic pain reported it reduced pain and decreased the need for opioid painkillers. Nine out of 10 liked it so much they said they’d recommend medical pot to others. “I was on Percocet and replaced it with medical marijuana. Thank you, thank you, thank you,” said one senior. Another patient put…
Read More →

Three Key Voices in the Medical Marijuana Industry

As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More →

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More →

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More →

Leave a Comment

You must be logged in to post a comment.